Bioequivalence studies on bisphosphonates: The example of alendronate

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 9 A, 2004, Pages 569-572

  Lainesse, Audrey ^a   Ozalp, Yildiz ^b   Wong, Hong ^a   Alpan, Recep Serdar ^b,c  

^a Anapharm Canada   (Canada)

^b EIS Eczacibasi Ilac Sanayi ve T   (Turkey)

^c Eczacibasi Ilac Pazarlama   (Turkey)

Author keywords

Alendronate, bioequivalence, clinical pharmacokinetics; Biphosphonates; CAS 121268 17 5; Osalen 10 mg

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; OSALEN;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG TOLERANCE; DRUG URINE LEVEL; FEMALE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TABLET FORMULATION; URINALYSIS; URINARY EXCRETION; VOMITING;

EID: 4644306016     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297050     Document Type: Article

References (12)

1. Jeal, W., Barradell, L. B., McTavish, D., Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs 53, 415 (1997)
2. Nussbaum, S. R., Warrell, R. P., Rude, R. et al., A dose response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J. Clin. Oncol. 11, 1618 (1993)
3. O'Doherty, D. P., Biockerstaff, D. R., McCloskey, E. V. et al., Treatment of Paget's disease of bone with aminohydroxybutilidene bisphosphonate. J. Bone Miner. Res., 5, 483 (1990)
4. Hughes, D. E., Wright, K. R., Uy, H. L., et al., Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10, 1478 (1995)
5. Porras, A. G., Holland, S. D., Gertz, B. J., Pharmacokinetics of alendronate. Clin. Pharmacokinet. 36, 315 (1999)
6. Cocquyt, V., Kline, W. F., Gertz, B. J., et al., Pharmacokinetics of intravenous alendronate. J. Clin. Pharmacol. 39, 385 (1999)
7. Shah, V. P., Midha, K. K., Digne, S. et al., Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharmaceut. Sci. 81, 309 (1992)
8. Lin, J. H., Duggan, D. E., Ellsworth, R. L., Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug. Metab. Dispos. 19, 926 (1991)
9. Lin, J. H., Chen, I. W., Duggan, D. E., Effect of dose, sex, and age on the disposition of alendronate, a potent anti-osteolytic bisphosphonate, in rats. Drug Metab. Dispos. 20, 473 (1992)
10. Gertz, B. J., Holland, S. D., Kline, W. F. et al., Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther. 58, 288 (1995)
11. Gertz, B. J., Holland, S. D., Kline, W. F., et al., Clinical pharmacology of alendronate sodium. Osteoporosis Int. 3 (Suppl. 3), 13 (1993)
12. CPMP Note for guidance: Investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98 (1998)